Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis

BACKGROUND: The elevated calcium and phosphorus levels in patients undergoing hemodialysis may increase the risk of all-cause mortality. Paricalcitol, as a new vitamin D receptor activator (VDRA), seemed to be effective in reducing the calcium and phosphorus levels. OBJECTIVES: The aim of this study...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Drug Des Devel Ther
Hlavní autoři: Liu, Yang, Liu, Ling-Yun, Jia, Ye, Wu, Mei-Yan, Sun, Yan-Yan, Ma, Fu-Zhe
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2019
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445244/
https://ncbi.nlm.nih.gov/pubmed/30992658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S176257
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky